Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model.

Kirkpatrick BD, Whitehead SS, Pierce KK, Tibery CM, Grier PL, Hynes NA, Larsson CJ, Sabundayo BP, Talaat KR, Janiak A, Carmolli MP, Luke CJ, Diehl SA, Durbin AP.

Sci Transl Med. 2016 Mar 16;8(330):330ra36. doi: 10.1126/scitranslmed.aaf1517. Epub 2016 Mar 16.

PMID:
27089205
2.

A 12-Month-Interval Dosing Study in Adults Indicates That a Single Dose of the National Institute of Allergy and Infectious Diseases Tetravalent Dengue Vaccine Induces a Robust Neutralizing Antibody Response.

Durbin AP, Kirkpatrick BD, Pierce KK, Carmolli MP, Tibery CM, Grier PL, Hynes N, Opert K, Jarvis AP, Sabundayo BP, McElvany BD, Sendra EA, Larsson CJ, Jo M, Lovchik JM, Luke CJ, Walsh MC, Fraser EA, Subbarao K, Whitehead SS.

J Infect Dis. 2016 Sep 15;214(6):832-5. doi: 10.1093/infdis/jiw067. Epub 2016 Feb 16.

3.

Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults.

Kirkpatrick BD, Durbin AP, Pierce KK, Carmolli MP, Tibery CM, Grier PL, Hynes N, Diehl SA, Elwood D, Jarvis AP, Sabundayo BP, Lyon CE, Larsson CJ, Jo M, Lovchik JM, Luke CJ, Walsh MC, Fraser EA, Subbarao K, Whitehead SS.

J Infect Dis. 2015 Sep 1;212(5):702-10. doi: 10.1093/infdis/jiv082. Epub 2015 Mar 22.

4.

A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial.

Durbin AP, Kirkpatrick BD, Pierce KK, Elwood D, Larsson CJ, Lindow JC, Tibery C, Sabundayo BP, Shaffer D, Talaat KR, Hynes NA, Wanionek K, Carmolli MP, Luke CJ, Murphy BR, Subbarao K, Whitehead SS.

J Infect Dis. 2013 Mar 15;207(6):957-65. doi: 10.1093/infdis/jis936. Epub 2013 Jan 17.

5.

Immune activation and IL-12 production during acute/early HIV infection in the absence and presence of highly active, antiretroviral therapy.

Byrnes AA, Harris DM, Atabani SF, Sabundayo BP, Langan SJ, Margolick JB, Karp CL.

J Leukoc Biol. 2008 Dec;84(6):1447-53. doi: 10.1189/jlb.0708438. Epub 2008 Sep 19.

6.

Guidelines for effective integration of information technology in the care of HIV-infected populations.

Magnus M, Herwehe J, Proescholdbell RJ, Lombard F, Cajina A, Dastur Z, Millery M, Sabundayo BP.

J Public Health Manag Pract. 2007 Jan-Feb;13(1):39-48.

PMID:
17149099
7.

High frequency of highly active antiretroviral therapy modifications in patients with acute or early human immunodeficiency virus infection.

Sabundayo BP, McArthur JH, Langan SJ, Gallant JE, Margolick JB.

Pharmacotherapy. 2006 May;26(5):674-81.

PMID:
16637796
9.

Anatomical loci of HIV-associated immune activation and association with viraemia.

Iyengar S, Chin B, Margolick JB, Sabundayo BP, Schwartz DH.

Lancet. 2003 Sep 20;362(9388):945-50.

PMID:
14511927
10.

Report on adherence from the XIV International AIDS Conference in Barcelona.

Sabundayo BP.

Hopkins HIV Rep. 2002 Nov;14(6):8-9, 12. No abstract available.

PMID:
12491992
11.

Screening for HIV infection in high-risk communities by urine antibody testing.

Hilton C, Sabundayo BP, Langan SJ, Hilton M, Henson C, Quinn TC, Margolick JB, Nelson KE.

J Acquir Immune Defic Syndr. 2002 Dec 1;31(4):416-21.

PMID:
12447013
12.

Association of Gag-specific T lymphocyte responses during the early phase of human immunodeficiency virus type 1 infection and lower virus load set point.

Patke DS, Langan SJ, Carruth LM, Keating SM, Sabundayo BP, Margolick JB, Quinn TC, Bollinger RC.

J Infect Dis. 2002 Oct 15;186(8):1177-80. Epub 2002 Sep 30.

PMID:
12355372
13.

Biphasic decay of latently infected CD4+ T cells in acute human immunodeficiency virus type 1 infection.

Blankson JN, Finzi D, Pierson TC, Sabundayo BP, Chadwick K, Margolick JB, Quinn TC, Siliciano RF.

J Infect Dis. 2000 Dec;182(6):1636-42. Epub 2000 Nov 8.

PMID:
11069234

Supplemental Content

Loading ...
Support Center